Polymorphids an mRNA Expression in Obese Genes
Polymorphids and mRNA Expression in Genes, Significant for Developing Obesity and Typ II Diabetes in Different Types/Localisations of Fat Tissue
1 other identifier
observational
50
1 country
2
Brief Summary
Fat tissue from omenta, thigh and abdomen taken under anesthesia on subjects undergoing laparoscopic surgery, cholecystectomy, reflux surgery or gastric by-pass (GBP). Are there any difference in polymorphids and/or mRNA expression in genes significant for developing obesity, between normal weight and obese individuals, with or without diabetes typ 2 . Are there any difference in polymorphids and/or mRNA expression in different types of fat tissue
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Jan 2010
Typical duration for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2010
CompletedFirst Submitted
Initial submission to the registry
October 9, 2012
CompletedFirst Posted
Study publicly available on registry
October 16, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
February 1, 2013
CompletedAugust 22, 2013
August 1, 2013
3.1 years
October 9, 2012
August 21, 2013
Conditions
Outcome Measures
Primary Outcomes (2)
Differences in polymorphids and/or mRNA expression in genes, significant for developing obesity and type 2 diabetes, between patients with normal weight and obesity
fat biopsy taken from abdomen, omenta and thigh at surgery
approximatly 30 minutes after start of operation
Difference in polymorphids and/or mRNA expression in different types of fat tissue in patients with normal weight or obesity with or without diabetes type 2
fat biopsy; abdomen, omenta and thigh taken at surgery
approximatly 30 minutes after start of operation
Study Arms (3)
Type 2 Diabetes and BMI>35
Patients with type 2 diabetes and body mass index 35 or more.
BMI>35
Patients undergoing surgery, gastric bypass or cholecystectomy, without diabetes type 2 and body mass index 35 or more
BMI 18-27
Patients undergoing surgery, cholecystectomy or reflux, without type 2 diabetes and body mass index between 18-27
Eligibility Criteria
Tree groups; group I: diabetes type II with BMI\>35 Group II: no diabetes BMI\>35 Group III: no diabetes BMI 18-27
You may qualify if:
- age 18 years or older
- laparoscopic surgery (Gastric by-pass, cholecystectomy, antireflux surgery)
- Normal weight without type 2 diabetes BMI 18-25
- Obese without type 2 diabetes BMI\>35
- Obese with type 2 diabetes BMI\>35
You may not qualify if:
- under 18 years
- open surgery
- pregnancy
- BMI \>27-\<35
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Ersta hospital
Stockholm, Stockholm County Council, 116 91, Sweden
Karolinska Institutet, CMM
Stockholm, 171 76, Sweden
Biospecimen
biopsys; Fat from oment, thigh and abdomen
Study Officials
- PRINCIPAL INVESTIGATOR
Anders Thorell, Ass. prof.
Karolinska Institutet
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associated professor, MD
Study Record Dates
First Submitted
October 9, 2012
First Posted
October 16, 2012
Study Start
January 1, 2010
Primary Completion
February 1, 2013
Study Completion
February 1, 2013
Last Updated
August 22, 2013
Record last verified: 2013-08